Sinopharm Group Co. Ltd.
1099
Rang in Aktien
#2998
Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of... Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support to both domestic and international manufacturers and suppliers in the pharmaceutical and healthcare sectors. The Medical Devices segment is solely focused on the distribution of various medical equipment. Through its Retail Pharmacy division, Sinopharm manages and franchises a vast chain of drug stores, with an impressive 10,259 locations as of December 31, 2021. The "Other Business" segment is involved in the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core areas, the company also engages in property rental and management. It further distributes specialized items such as medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Sinopharm provides a comprehensive array of services, including IT development, medicine and health consultations, investment services, import/export facilitation for goods and technology, various business and market information consulting, and the organization of conventions and exhibitions. Moreover, it oversees medical project investments, offers related consulting, and provides technological training. Notably, Sinopharm Group has established a strategic alliance with I-Mab to enhance its commercial capabilities and accelerate its market entry strategies. Founded in Shanghai, China, in 2003, Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Aktienkurs
$1.97
Marktkapitalisierung
$6.14B
Veränderung (1 Tag)
-2.23%
Veränderung (1 Jahr)
-18.37%
Land
CN
Handel Sinopharm Group Co. Ltd. (1099)
Kategorie
Healthcare
Gewinn für Sinopharm Group Co. Ltd. (1099)
Gewinn im Jun 2026 TTM: $2.09B
Laut den aktuellen Finanzberichten von Sinopharm Group Co. Ltd. betragen die aktuellen Gewinne des Unternehmens $2.09B. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $2.76B, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $2.69B betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Sinopharm Group Co. Ltd. von 2006 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $2.09B | 9.08% |
| 2024 | $1.92B | -30.41% |
| 2023 | $2.76B | 2.43% |
| 2022 | $2.69B | 0.60% |
| 2021 | $2.68B | 12.04% |
| 2020 | $2.39B | 20.83% |
| 2019 | $1.98B | 11.34% |
| 2018 | $1.77B | 13.51% |
| 2017 | $1.56B | 21.64% |
| 2016 | $1.29B | 11.76% |
| 2015 | $1.15B | 20.05% |
| 2014 | $958.13M | 25.78% |
| 2013 | $761.73M | 18.33% |
| 2012 | $643.74M | 29.76% |
| 2011 | $496.12M | 36.56% |
| 2010 | $363.30M | 57.74% |
| 2009 | $230.31M | 45.87% |
| 2008 | $157.89M | 40.52% |
| 2007 | $112.36M | 140.98% |
| 2006 | $46.62M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $6.46B | 208.64% |
US
|
|
| - | - |
US
|
|
| $2.17B | 3.90% |
US
|
|
| - | - |
US
|
|
| $708.86M | -66.12% |
AU
|
